Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old.
Specific Aims:
Determine if goji berry intake for 90 days, 5 times per week, will:
The investigators hypothesize that the intake of 28 grams of goji berry for 90 days, 5 days per week will significantly increase MPOD after three months, compared to baseline values. In contrast, the investigators hypothesize that a dietary supplement of lutein and zeaxanthin will not alter MPOD.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Macular Pigment Optical Density | Dietary Supplement: Goji berry Dietary Supplement: Lutein + zeaxanthin supplementation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 31 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized paralleled arm clinical trial |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function |
Actual Study Start Date : | June 10, 2019 |
Actual Primary Completion Date : | May 28, 2020 |
Actual Study Completion Date : | June 15, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Goji berry
The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0 SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with either a 45-day supply of goji berries and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
|
Dietary Supplement: Goji berry
Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
|
Active Comparator: Lutein + zeaxanthin supplementation
The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
|
Dietary Supplement: Lutein + zeaxanthin supplementation
Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
|
Ages Eligible for Study: | 45 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion:
Male and female:45-65 years Willing and able to comply with the study protocols Normal macular condition verified by optometry office Stable on prescription medication use, for at least the past 6 months, as approved by the study physician
Exclusion:
Dislike of or allergy to goji berry Self-reported diabetes, renal or liver disease, heart disease, which includes cardiovascular events and stroke, cancer, malabsorption problems, substance abuse or eye diseases
Smoking:
Currently taking zeaxanthin or lutein supplements Use of multi-vitamin and mineral supplements other than a general formula that provides up to 100% of the Daily Value Not willing to stop dietary supplement use at least one month prior to study enrollment Currently taking drugs for management of lipids, glucose or blood pressure statin drugs A current enrollee in a clinical research study
United States, California | |
Regal Human Nutrition Research Center | |
Davis, California, United States, 95616 |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | June 7, 2019 | ||||||
First Posted Date ICMJE | June 12, 2019 | ||||||
Last Update Posted Date | July 23, 2020 | ||||||
Actual Study Start Date ICMJE | June 10, 2019 | ||||||
Actual Primary Completion Date | May 28, 2020 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Macular pigment ocular density (MPOD) [ Time Frame: 90 days ] MPOD measurement - MPOD will be assessed by the psychophysical method of HFP technology (Macular Metrics, Providence, RI). Participants will watch a 20 minutes long video of a description of HFP. After adapting to the dark for seven minutes, participants will be asked to rest their head on a chin rest and look at a blue background field for three minutes. Prior to each test, the light intensity from each wavelength will be calibrated with a photodiode. The flicker frequency is selected for each subject based on preliminary tests of flicker sensitivity. The observer's task is to eliminate or minimize the flicker by turning a dial that changes the intensity of the 460-nm light. They will be asked to do this when looking directly at the flickering light and also when looking at a fixation point so that the stimulus can be presented in the periphery.
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function | ||||||
Official Title ICMJE | The Effect of Gojiberry Intake (Lycium Barbarium) on Macular Function | ||||||
Brief Summary |
Objective: To evaluate the effects of goji berry intake for three months on macular pigment ocular density (MPOD) between 45 and 65 years old. Specific Aims: Determine if goji berry intake for 90 days, 5 times per week, will:
The investigators hypothesize that the intake of 28 grams of goji berry for 90 days, 5 days per week will significantly increase MPOD after three months, compared to baseline values. In contrast, the investigators hypothesize that a dietary supplement of lutein and zeaxanthin will not alter MPOD. |
||||||
Detailed Description |
Prior to enrollment, all volunteers that meet the initial inclusion and exclusion based on a telephone interview will be asked to participate in a clinical screening visit, which will assess the subject's overall health, and whether the individual meets the inclusion and exclusion criteria. To determine normal eye health, subjects will provide a statement from their optometrist verifying normal functioning. The study will be conducted in the Ragle Human Nutrition Research Center on the UC Davis campus. The participants will be consented into the study. For those who are not familiar with goji berry, a sample tasting will be provided. In addition, each volunteer will be asked to complete a diet and health habits questionnaire. The first study visit will begin on the same day after the screening visit is done. The study will be a randomized, controlled, parallel arm design with two groups: goji berry or lutein/zeaxanthin (L/Z) supplement. Participants will be randomly assigned to one of the two groups using a block design that will place an approximately similar number of males and females in each group. The randomization will be conducted by an online tool called Research Randomizer. The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0, SV2 conducted at day 45, and SV3 conducted at day 90. The first study visit will occur immediately after consent is completed. Depending on group assignment, the participant will be provided with either a 45-day supply of goji berries or L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3). Participants will complete a log in order to verify compliance. Dietary recall will be collected by using the Automated Self-Administered 24-hour dietary assessment (ASA24) web-based tool between each SV. MPOD measurement - MPOD will be assessed by the psychophysical method of HFP technology (Macular Metrics, Providence, RI). Participants will watch a 20 minutes long video of a description of HFP. After adapting to the dark for seven minutes, participants will be asked to rest their head on a chin rest and look at a blue background field for three minutes. Prior to each test, the light intensity from each wavelength will be calibrated with a photodiode. The flicker frequency is selected for each subject based on preliminary tests of flicker sensitivity. The observer's task is to eliminate or minimize the flicker by turning a dial that changes the intensity of the 460-nm light. They will be asked to do this when looking directly at the flickering light and also when looking at a fixation point so that the stimulus can be presented in the periphery. Skin carotenoid measurement - the carotenoid content in the skin will be measured through a finger-scanning device using reflection spectroscopy (this process does not capture fingerprints) called the Veggie Meter (VM). This noninvasive method of measuring skin carotenoid levels has been validated to reflect plasma carotenoid concentrations. Breath Hydrogen measurement - the participant will be asked to do one short exhalation (about 2-3 seconds) into a collection tube. Their breath sample will be analyzed for hydrogen and methane that are produced by fermentation of carbohydrates (including fiber) in the digestive tract. Compliance will be assessed verbally and through self-reported logs indicating consumption of the product. Dietary recall will be collected by using the Automated Self-Administered 24-hour dietary assessment (ASA24) web-based tool during each study arm, and a weekly log book of digestive tract symptoms, which will record a typical symptom such as bloating, gas, intestinal cramps, and loose stools. |
||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Randomized paralleled arm clinical trial Masking: None (Open Label)Primary Purpose: Prevention |
||||||
Condition ICMJE | Macular Pigment Optical Density | ||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
31 | ||||||
Original Estimated Enrollment ICMJE |
30 | ||||||
Actual Study Completion Date ICMJE | June 15, 2020 | ||||||
Actual Primary Completion Date | May 28, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion: Male and female:45-65 years Willing and able to comply with the study protocols Normal macular condition verified by optometry office Stable on prescription medication use, for at least the past 6 months, as approved by the study physician Exclusion: Dislike of or allergy to goji berry Self-reported diabetes, renal or liver disease, heart disease, which includes cardiovascular events and stroke, cancer, malabsorption problems, substance abuse or eye diseases Smoking:
Currently taking zeaxanthin or lutein supplements Use of multi-vitamin and mineral supplements other than a general formula that provides up to 100% of the Daily Value Not willing to stop dietary supplement use at least one month prior to study enrollment Currently taking drugs for management of lipids, glucose or blood pressure statin drugs A current enrollee in a clinical research study |
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 45 Years to 65 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03983525 | ||||||
Other Study ID Numbers ICMJE | 1220178 | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Responsible Party | University of California, Davis | ||||||
Study Sponsor ICMJE | University of California, Davis | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE | Not Provided | ||||||
PRS Account | University of California, Davis | ||||||
Verification Date | July 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |